Welcome to our dedicated page for Regulus Therapeu news (Ticker: RGLS), a resource for investors and traders seeking the latest updates and insights on Regulus Therapeu stock.
Regulus Therapeutics Inc. (RGLS) is a biopharmaceutical innovator focused on developing microRNA-targeted therapies through advanced oligonucleotide technology. This page serves as the definitive source for official company announcements, research milestones, and regulatory developments.
Investors and researchers will find timely updates on clinical trial progress, including the Phase 1b study of RGLS8429 for autosomal dominant polycystic kidney disease (ADPKD). Our curated news collection provides essential insights into therapeutic advancements, partnership agreements, and strategic initiatives shaping the company's trajectory.
The repository features rigorously verified information across key categories: clinical program updates, financial disclosures, intellectual property developments, and scientific publications. Each entry maintains factual accuracy while highlighting implications for Regulus' position in the precision medicine landscape.
Bookmark this page for direct access to primary source materials from Regulus Therapeutics. Regularly updated content ensures stakeholders maintain current understanding of the company's progress in addressing complex diseases through RNA-targeted therapeutics.
Regulus Therapeutics (Nasdaq: RGLS) has initiated dosing in a Phase 1b clinical study of RGLS4326 for patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). This study aims to assess safety, pharmacokinetics, and biomarker changes in up to three cohorts. The first cohort will consist of nine patients receiving RGLS4326 biweekly for six weeks, with results expected by the end of Q1 2021. Regulus aims to use these results to address FDA requirements for extended-duration studies. RGLS4326 targets microRNAs to elevate polycystin levels linked to ADPKD.
Regulus Therapeutics (Nasdaq: RGLS) announced the receipt of $5 million from Sanofi as part of milestone and material payments related to its miR-21 programs. The company utilized these funds to pay down its term loan to approximately $9.6 million. Regulus is eligible for additional payments, including $5 million upon achieving an interim milestone and $25 million for a development milestone. The loan agreement with Oxford includes provisions for an additional interest-only period if the company pays down another $5 million by April 30, 2021.
Regulus Therapeutics Inc. (Nasdaq: RGLS) announced that CEO Jay Hagan will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 11:00 AM EDT. This presentation will focus on the company’s innovative medicines targeting microRNAs. A live webcast will be available on the company’s investor relations website. Regulus specializes in oligonucleotide drug development and holds a robust intellectual property portfolio in the microRNA field.
Regulus Therapeutics Inc. (Nasdaq: RGLS) announced that CEO Jay Hagan will present at the Wells Fargo Virtual Healthcare Conference on September 9, 2020, at 10:40 AM EDT. The event will be accessible via a live webcast on the company's website. Regulus focuses on developing medicines targeting microRNAs and possesses a robust intellectual property portfolio. The company is based in La Jolla, California.
Regulus Therapeutics Inc. (Nasdaq: RGLS) announced amendments to its loan agreement with Oxford LLC, allowing for up to seven months of interest-only payments if $10 million in principal is paid by April 30, 2021. Concurrently, the company restructured its agreement with Sanofi, resulting in a $1 million sale of materials and potential milestone payments totaling $9 million, with an additional $25 million milestone related to miR-21 compounds. CEO Jay Hagan expressed optimism about these agreements, which aim to ease financial pressures and extend operational flexibility.
Regulus Therapeutics (Nasdaq: RGLS) reported its Q2 2020 financial results, noting a net loss of $6.9 million, or $0.23 per share. Revenue was negligible, down from $6.8 million in Q2 2019. The company highlighted progress in its ADPKD program with the completion of the dosing for RGLS4326 in a clinical study. Additionally, RGLS4326 received Orphan Drug Designation from the FDA. The firm also announced advancements in its Hepatitis B program, where a lead compound demonstrated significant efficacy in preliminary studies.
Regulus Therapeutics Inc. (Nasdaq: RGLS) has announced that CEO Jay Hagan will present at the Wedbush PacGrow Healthcare Virtual Conference on August 12, 2020, at 2:20 PM EDT. Regulus focuses on innovative medicines targeting microRNAs, leveraging its expertise in oligonucleotide drug discovery. The company is based in La Jolla, California, and is actively engaged in preclinical and clinical studies, particularly with the RGLS4326 program. Forward-looking statements regarding its business, particularly amidst the COVID-19 pandemic, emphasize risks and uncertainties that could impact its operations.
Regulus Therapeutics (Nasdaq: RGLS) announced the appointment of Denis Drygin, Ph.D., as Chief Scientific Officer effective August 3, 2020. Dr. Drygin brings nearly 20 years of experience in drug discovery and development, previously serving at Pimera and Cylene Pharmaceuticals. CEO Jay Hagan expressed confidence in Dr. Drygin's expertise to enhance Regulus' innovative microRNA therapeutics pipeline. This strategic hire aims to strengthen the company's position in addressing high unmet medical needs in various indications.
Regulus Therapeutics (Nasdaq: RGLS) announced that the FDA has granted Orphan Drug Designation to its drug RGLS4326 for treating Autosomal Dominant Polycystic Kidney Disease (ADPKD). This designation offers significant benefits, including seven years of market exclusivity upon FDA approval, tax credits, and fee waivers. RGLS4326 is designed to inhibit miR-17 and targets the kidneys, demonstrating promising preclinical results in reducing cyst growth. A Phase 1b study for RGLS4326 in ADPKD patients is set to evaluate its safety and pharmacokinetics.
Regulus Therapeutics Inc. (Nasdaq: RGLS) announced the successful completion of the Phase 1 multiple ascending dose study for RGLS4326, focusing on safety and tolerability in healthy volunteers. The study showed that RGLS4326 was well-tolerated with no serious adverse events reported, leading to plans for a Phase 1b open-label study in patients with autosomal dominant polycystic kidney disease (ADPKD). This upcoming study aims to evaluate the drug's safety and its potential to enhance biomarkers related to ADPKD, with results expected within six weeks after dosing.
FAQ
What is the current stock price of Regulus Therapeu (RGLS)?
What is the market cap of Regulus Therapeu (RGLS)?
